Protalix BioTherapeutics (PLX) Liabilities from Discontinued Operations (2014 - 2016)

Protalix BioTherapeutics has reported Liabilities from Discontinued Operations for 3 years, with the latest figure at 293000.0 in Q2 2016.

• For the quarter ending Q2 2016, Liabilities from Discontinued Operations changed N/A year-over-year to 293000.0; the trailing twelve-month figure through Jun 2016 stood at 293000.0 (changed N/A YoY), and the FY2015 full-year result was 1568000.0, down 97.03% from the prior year.
• Liabilities from Discontinued Operations for Q2 2016 stood at 293000.0, up from 128000.0 in the prior quarter.
• The five-year high for Liabilities from Discontinued Operations was 52830000.0 in Q4 2014, with the low at 128000.0 in Q1 2016.
• Average Liabilities from Discontinued Operations over 3 years is 13704750.0, with a median of 930500.0 recorded in 2015.
• Peak annual rise in Liabilities from Discontinued Operations reached 97.03% in 2015, while the deepest fall reached 97.03% in 2015.
• Tracing PLX's Liabilities from Discontinued Operations over 3 years: stood at 52830000.0 in 2014, then tumbled by 97.03% to 1568000.0 in 2015, then slumped by 81.31% to 293000.0 in 2016.
• The last three Liabilities from Discontinued Operations figures came in at 293000.0 (Q2 2016), 128000.0 (Q1 2016), and 1568000.0 (Q4 2015), per Business Quant data.

Peer Comparison